Log In | Register
GlaxoSmithKline and FDA notified healthcare professionals of a new safety finding in patients with thrombocytopenia due to chronic liver disease treated with eltrombopag, a thrombopoietin receptor agonist approved for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura.
Promacta (eltrombopag): Portal Venous System Thromboses in Study of Patients With Chronic Liver Disease
Seeded on Wed May 12, 2010 8:43 PM EDT
Article Source: Food and Drug Administration Press Releases- Enjoy this article? Help vote it up the 'Vine.
- Public Discussion (0)
You're in Easy Mode. If you prefer, you can use XHTML Mode instead. |
As a new user, you may notice a few temporary content restrictions. Click here for more info.
